论文部分内容阅读
目的:探讨血清CA19-9,CA-50,CEA联合检测对胰腺癌的诊断价值。方法:采用酶联免疫测定法和CA-50抗原免疫放射分析法对27例胰腺癌、19例肝癌和37例胃肠癌、30例消化道良性疾病患者血清CA-19、CA-50和CEA水平进行测定,并对胰腺癌、肝癌、胃肠癌及消化道良性疾病患者血清三项标志物的水平进行比较。结果:消化道恶性肿瘤组的血清CA19-9、CA-50、CEA水平明显高于消化道良性疾病组(P<005),尤以胰腺癌为著(P<001)。还发现肿瘤三项标志物联合测定阳性者(CEA>12ng/ml、CA19-9>37u/ml、CA-50>20u/ml三项中两项超过正常值或单项超过其两倍以上者)胰腺癌组占8889%,与其单检阳性率(4444%)相比有显著性差异(P<0005)。肝癌与胃肠癌两组的肿瘤标志物联检阳性率与单检阳性率相比均无显著性差异(P>005)。结论:血清CA19-9、CA-50和CEA联合检测对胰腺癌的诊断有重要价值。可明显提高胰腺癌的确诊率
Objective: To investigate the diagnostic value of combined detection of serum CA19-9, CA-50 and CEA in pancreatic cancer. Methods: The serum levels of CA-19, CA-50 and CEA in 27 cases of pancreatic cancer, 19 cases of hepatocellular carcinoma and 37 cases of gastrointestinal cancer and 30 cases of benign gastrointestinal diseases were detected by enzyme-linked immunosorbent assay and CA-50 antigen immunoassay. Levels were measured, and pancreatic cancer, liver cancer, gastrointestinal cancer and gastrointestinal benign disease in patients with serum levels of three markers were compared. Results: Serum levels of CA19-9, CA-50 and CEA in gastrointestinal malignant group were significantly higher than those in benign gastrointestinal tract group (P <005), especially in pancreatic cancer (P <0.001). Also found three tumor markers were positive (CEA> 12ng / ml, CA19-9> 37u / ml, CA-50> 20u / ml three out of the three normal or more than two times more than two) Pancreatic cancer accounted for 8889%, which was significantly different from the single positive rate (4444%) (P <0005). There was no significant difference in the positive rate of tumor markers between liver cancer and gastrointestinal cancer (P> 0.05). Conclusion: The combined detection of serum CA19-9, CA-50 and CEA is of great value in the diagnosis of pancreatic cancer. Can significantly improve the diagnosis of pancreatic cancer